New Horizons in the Diagnosis and Treatment of Hereditary Angioedema: Overcoming Barriers to Management and Improving Patient Outcomes

https://www.pharmacytimes.org/on-demand/new-horizons-in-the-diagnosis-and-treatment-of-hereditary-angioedema

Related Videos

Related Content

Advertisement

May 20th 2025

Mepolizumab Reduces COPD Exacerbations in Patients With Eosinophilic Inflammation

Hayden E. Klein

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of life in patients with eosinophilic chronic obstructive pulmonary disease (COPD).

May 20th 2025

Mental Health Awareness: Transforming Workplace Support and Engagement

Giuliana Grossi Jim Kinville

Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.

May 20th 2025

The Last 5 Years: Lessons in Progressive Pulmonary Fibrosis Treatment

Hayden E. Klein

Researchers are working to redefine diagnosis and treatment with data-driven tools aimed at identifying patients earlier and guiding precision care.

May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS

Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.

May 20th 2025

HHS Sets Pricing Target for Trump’s Most Favored Nation Drug Price Model

Laura Joszt, MA

Following President Trump's Most Favored Nation executive order, HHS and CMS have released the target price for pharmaceutical manufacturers to meet.

May 20th 2025

Weighing Drug Costs and Patient Values in Cancer Care

Mary Caffrey

Related Content

Advertisement

May 20th 2025

Mepolizumab Reduces COPD Exacerbations in Patients With Eosinophilic Inflammation

Hayden E. Klein

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of life in patients with eosinophilic chronic obstructive pulmonary disease (COPD).

May 20th 2025

Mental Health Awareness: Transforming Workplace Support and Engagement

Giuliana Grossi Jim Kinville

Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.

May 20th 2025

The Last 5 Years: Lessons in Progressive Pulmonary Fibrosis Treatment

Hayden E. Klein

Researchers are working to redefine diagnosis and treatment with data-driven tools aimed at identifying patients earlier and guiding precision care.

May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS

Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.

May 20th 2025

HHS Sets Pricing Target for Trump’s Most Favored Nation Drug Price Model

Laura Joszt, MA

Following President Trump's Most Favored Nation executive order, HHS and CMS have released the target price for pharmaceutical manufacturers to meet.

May 20th 2025

Weighing Drug Costs and Patient Values in Cancer Care

Mary Caffrey